🟢 Nyxoah is trading 17.85% up in pre-market after ACCCESS study meets safety and efficacy endpoints

Nyxoah is trading 17.85% up at $1.78 after its September 2, 2026 announcement that the ACCCESS U.S. pivotal study met primary safety and efficacy endpoints.

• 12-month AHI and ODI responder rates were 77.2% and 87.7%; zero device-related serious adverse events were reported.
• Results support planned FDA submission for expanded Genio eligibility in complete concentric collapse patients.
• The move followed a company-specific September 2 post-close update, not broader market strength; fuller results are expected at an October 2026 sleep-surgery meeting.